- Home
- IGMS vs MAMO Comparison
IGMS vs MAMO Comparison
Compare IGMS & MAMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- MAMO
- Stock Information
- Founded
- IGMS 1993
- MAMO 2008
- Country
- IGMS United States
- MAMO United States
- Employees
- IGMS N/A
- MAMO N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- MAMO
- Sector
- IGMS Health Care
- MAMO
- Exchange
- IGMS Nasdaq
- MAMO NYSE
- Market Cap
- IGMS 82.1M
- MAMO 91.0M
- IPO Year
- IGMS 2019
- MAMO 2024
- Fundamental
- Price
- IGMS $1.36
- MAMO $2.79
- Analyst Decision
- IGMS Hold
- MAMO
- Analyst Count
- IGMS 8
- MAMO 0
- Target Price
- IGMS $6.00
- MAMO N/A
- AVG Volume (30 Days)
- IGMS 1.1M
- MAMO 28.4K
- Earning Date
- IGMS 08-13-2025
- MAMO 08-11-2025
- Dividend Yield
- IGMS N/A
- MAMO N/A
- EPS Growth
- IGMS N/A
- MAMO N/A
- EPS
- IGMS N/A
- MAMO N/A
- Revenue
- IGMS $2,681,000.00
- MAMO $95,959,187.00
- Revenue This Year
- IGMS $134.30
- MAMO N/A
- Revenue Next Year
- IGMS $22.37
- MAMO N/A
- P/E Ratio
- IGMS N/A
- MAMO N/A
- Revenue Growth
- IGMS 27.36
- MAMO N/A
- 52 Week Low
- IGMS $0.92
- MAMO $1.84
- 52 Week High
- IGMS $22.50
- MAMO $4.66
- Technical
- Relative Strength Index (RSI)
- IGMS 59.58
- MAMO N/A
- Support Level
- IGMS $1.12
- MAMO N/A
- Resistance Level
- IGMS $1.39
- MAMO N/A
- Average True Range (ATR)
- IGMS 0.08
- MAMO 0.00
- MACD
- IGMS 0.01
- MAMO 0.00
- Stochastic Oscillator
- IGMS 83.87
- MAMO 0.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About MAMO MASSIMO GROUP
Massimo Group is engaged in the mid-tier band the (Mid-Tier Band) of the Powersports Vehicles and Boats Industry. It manufacture, import and distribute a diversified portfolio of products divided into two main lines: a motor sports brand consisting of utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), motorcycles, scooters, golf carts, and a juvenile line from go karts to balance bikes; and a motor boat line consisting of pontoon and tritoon boats (Pontoon Boats).